# AMAG Pharmaceuticals, Inc. clinical trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with AMAG Pharmaceuticals, Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AMAG Pharmaceuticals, Inc.: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/amag-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2020 | NCT04593784 | Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults | AMAG Pharmaceuticals, Inc. | Phase 2 | Terminated | Healthy | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04593784) |
| June 4, 2019 | NCT03973047 | Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran | AMAG Pharmaceuticals, Inc. | Phase 1 | Completed | Nausea | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03973047) |
| March 28, 2019 | NCT03893045 | A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects | AMAG Pharmaceuticals, Inc. | Phase 3 | Recruiting | Iron Deficiency Anemia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03893045) |
| August 8, 2018 | NCT03619850 | A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron... | AMAG Pharmaceuticals, Inc. | Phase 3 | Recruiting | Chronic Kidney Disease; Iron Deficiency Anemia | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03619850) |
| January 2, 2017 | NCT03008616 | Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia | AMAG Pharmaceuticals, Inc. | Phase 2/3 | Terminated | Severe Preeclampsia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03008616) |
| October 21, 2016 | NCT02940522 | Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an... | AMAG Pharmaceuticals, Inc. | Phase 1 | Completed | Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02940522) |
| October 19, 2016 | NCT02937766 | Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous... | AMAG Pharmaceuticals, Inc. | Phase 3 | Terminated | Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02937766) |
| March 1, 2016 | NCT02694978 | A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 2,014 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02694978) |
| December 22, 2010 | NCT01264679 | A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease | AMAG Pharmaceuticals, Inc. | Phase 3 | Terminated | Iron Deficiency Anemia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01264679) |
| October 25, 2010 | NCT01227616 | Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis | AMAG Pharmaceuticals, Inc. | Phase 4 | Completed | Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD) | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01227616) |
| July 1, 2010 | NCT01155388 | A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Nondialysis-Dependent Chronic Kidney... | AMAG Pharmaceuticals, Inc. | Phase 3 | Terminated | Iron Deficiency Anemia, Nondialysis-dependent Chronic Kidney Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01155388) |
| July 1, 2010 | NCT01155375 | A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease | AMAG Pharmaceuticals, Inc. | Phase 3 | Terminated | Iron Deficiency Anemia | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01155375) |
| June 22, 2010 | NCT01146990 | A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone... | AMAG Pharmaceuticals, Inc. | Observational | Completed | Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01146990) |
| May 3, 2010 | NCT01114217 | A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 634 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01114217) |
| May 3, 2010 | NCT01114204 | A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 605 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01114204) |
| April 30, 2010 | NCT01114139 | A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 812 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01114139) |
| January 20, 2010 | NCT01052779 | A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease | AMAG Pharmaceuticals, Inc. | Phase 2 | Completed | Iron Deficiency, Anemia, Kidney Disease | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01052779) |
| October 29, 2009 | NCT01004029 | Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Preterm Birth | 1,740 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01004029) |
| July 1, 2008 | NCT00707876 | Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD) | AMAG Pharmaceuticals, Inc. | Phase 2 | Completed | Peripheral Arterial Disease (PAD) | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00707876) |
| August 4, 2006 | NCT00360425 | A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women | AMAG Pharmaceuticals, Inc. | Phase 1 | Completed | Anemia | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00360425) |
| November 21, 2005 | NCT00255450 | A Crossover Safety Study of Ferumoxytol Versus Placebo | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Anemia | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00255450) |
| November 21, 2005 | NCT00255437 | Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Anemia | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00255437) |
| November 21, 2005 | NCT00255424 | Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Anemia | 304 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00255424) |
| October 6, 2005 | NCT00233597 | Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients | AMAG Pharmaceuticals, Inc. | Phase 3 | Completed | Anemia | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00233597) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 15 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 6 |
| Recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia, Iron-Deficiency | 11 |
| Anemia | 7 |
| Renal Insufficiency, Chronic | 4 |
| Peripheral Arterial Disease | 1 |
| Pre-Eclampsia | 1 |
| Iron Deficiencies | 1 |
| Kidney Diseases | 1 |
| Nausea | 1 |
| Premature Birth | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Energy management companies in the United States](https://specstream.ai/data/businesses/energy-management-companies/united-states)
- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Venezuelan restaurants in the United States](https://specstream.ai/data/businesses/venezuelan-restaurants/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
